United States was Teva Pharmaceutical Industries’s largest region in fiscal 2025, bringing in $7.08B of $12.12B (58%).
| Geography | FY 2008 | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | — | — | — | |||||||||||||
| United States | $5.55B | $6.33B | $7.08B | |||||||||||||
| Salesrevenuenet | — | — | — | |||||||||||||
| Europe | $4.84B | $5.10B | $5.04B | |||||||||||||
| Total | $10.39B | $11.43B | $12.12B |
Teva Pharmaceutical Industries brought in $12.12B from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 6.0% from $11.43B in fiscal 2024. United States was the largest at $7.08B (58.4%), ahead of Europe at $5.04B (41.6%).
Compared with fiscal 2024, United States grew 11.9% to $7.08B, while Europe fell 1.2% to $5.04B. From fiscal 2023 to 2025, combined revenue from these regions grew from $10.39B to $12.12B, a compound annual growth rate of 8.0%. United States' share of the total rose from 53.5% to 58.4%.
Teva Pharmaceutical Industries (TEVA) reports its revenue by geography. In fiscal 2025, United States was its largest region, bringing in $7.08B (58.4% of the total), followed by Europe at $5.04B (41.6%).
United States was Teva Pharmaceutical Industries' largest region in fiscal 2025, bringing in $7.08B, or 58.4% of the $12.12B total across its two regions.
United States grew faster than Europe in fiscal 2025, up 11.9% from $6.33B to $7.08B. Europe fell 1.2% to $5.04B.
Every figure comes from Teva Pharmaceutical Industries' annual financial filings, as reported. Each line keeps the name Teva Pharmaceutical Industries gives it, and years follow its fiscal calendar.
Teva Pharmaceutical Industries' revenue by geography goes back to fiscal 2008, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.